Results 131 to 140 of about 5,524,771 (289)
Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra +8 more
wiley +1 more source
Effects of Metabolic Factors on Left Ventricular Diastolic Function in Patients with Obstructive Sleep Apnea [PDF]
Yi-Fan Zhou,1,* Shu-Han Chen,1,* Wan-Da Wang,1 Jia-Le Chen,1 Ping-Yu Cai,1 Mei-Mei Li,1 Yue-Ling Lin,1 Wan-Qi Li,1 De-Hong Huang,1 Jun Li,1 Yue-Ting Li,2 Hui-Li Lin1 1Department of Cardiology, The Second Affiliated Hospital of Fujian Medical ...
Li YT +11 more
core
Acutely lowering salivary pH (with sugar‐containing acidic gum vs. sugar‐free gum) augments salivary nitrate reduction to nitrite, plasma nitrite concentration, and blood pressure lowering with dietary nitrate. Modifying salivary pH reveals a mechanism by which the nitrate‐nitrite‐NO pathway may be upregulated/inhibited, with potential for other ...
Andrew J. Webb +7 more
wiley +1 more source
Biomarkers of ventricular remodelling in African hypertensives. [PDF]
Includes abstract.Includes bibliographical references.There is substantial evidence that the burden of hypertension, hypertension with left ventricular hypertrophy and hypertensive heart failure is very enormous in sub-Saharan Africa.
Dike, Ojji
core
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz +7 more
wiley +1 more source
COPD advances in left ventricular diastolic dysfunction
Yoshiaki Kubota,1 Kuniya Asai,1 Koji Murai,1 Yayoi Tetsuou Tsukada,1 Hiroki Hayashi,2 Yoshinobu Saito,2 Arata Azuma,2 Akihiko Gemma,2 Wataru Shimizu1 1Department of Cardiovascular Medicine, 2Department of Pulmonary Medicine and Oncology, Graduate School
Gemma A +8 more
core
Development of a nalmefene formulation suitable for a community‐use auto‐injector
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano +6 more
wiley +1 more source
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies +2 more
wiley +1 more source
SC Heslinga,1,2 TC Konings,3 IE van der Horst-Bruinsma,1,2 O Kamp,3 VP van Halm,3,4 HACM de Bruin-Bon,4 MJ Peters,5 MT Nurmohamed1,2 1Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands; 2Department
Konings TC +7 more
core

